Stating that its “digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care”, Cambridge Cognition (COG) has announced that its 35p per share “retail offer launched on 24 June 2026 has now closed”. With the shares having been 43.5p earlier this year and having commenced this month at 37p, a good take-up?
Cambridge Cognition (COG) “is pleased to announce… it has conditionally raised approximately £2.54 million (before expenses)… at the issue price of 35.0 pence per share. In addition, the company intends to provide existing retail shareholders with the opportunity to participate via the retail offer to raise up to £0.5 million”. How ‘pleasing’ is this?
Start of this month-announced results from health technology company Cambridge Cognition (COG) included it having “adopted a going concern basis of accounting and, in doing so, have considered the cash requirement of the group through to the period ended 30 June 2025… Delays to orders that reduce cash below the downside case are likely to require the need to raise additional funds for working capital”. And now a placing, subscription and open offer. Significant delays to orders already then?
Cambridge Cognition (COG) states that it “is pleased to announce its preliminary unaudited results for the year ended 31 December 2023 as well as an update on its outlook and current trading”. So why are the shares down from approaching 95p in September and currently a further more than 5% today at 48.5p?
Hello Share Spillers. A company with the rather clumsy name of Cambridge Cognition Holdings (COG) appears worth a look. It’s a niche medical outfit that assists in organising clinical trials for drugs and treatments. Since Covid, there’s a sharper focus on the medical sector and more money being spent on it.
Hello Share Scrapers. It’s my often-voiced opinion that many companies in the medical sphere are worth a peek in these dangerous days. And that’s because Covid makes the world more aware of the value of good health. My latest commendation in this blazing field is a company that performs the essential service of helping to test new drugs.
Having filed patents and announced the start of the technology programme last year, Cambridge Cognition (COG) has now announced its “first voice-based cognitive assessments are available for use in its core pharmaceutical and biotechnology clinical trial channels”…
The theme of Monday's UK Investor City Show evening was disruptive technologies. That is certainly something Cambridge Cognition (COG) is working on. Nigel Wray is a big shareholders and has increased his stake of late. Watch the video to see why.
This is from HotStockRockets at the end of last month; tipped at a 145p offer price, and now circa 170p - to catch such articles first click HERE... To see Britain’s Buffett, Nigel Wray, at the top of the shareholders list is always an encouraging sign and with Cambridge Cognition (COG) this is added to by recent developments…
Having listed on AIM in 2013 at 70p per share to “accelerate the rollout of CANTABmobile, our point of care cognitive test for GPs and dementia specialists”, shares in Cambridge Cognition (COG) currently trade approaching 20% lower today at around 55p on the back of a “Trading Update” including the company “not quite meeting earnings expectations for 2015”. This though follows a November update on expected contracts to “ensure that, despite increasing investment in both healthcare technology development and commercial infrastructure in the USA, the outturn for this year should be similar to 2014 and provide a strong contracted revenue base for the next fiscal year”. Hmmm…
It has to be said, that if nothing else Cambridge Cognition Holdings has an intellectual / boffin type of ring to it. On a more “scientific” charting view we can see what is clearly a relatively lightly traded stock over the past year, but one that looks to be in recovery mode.
